Base Biotech Raises “Tens of Millions of Dollars” in A1 Round for Base Editing

In January, Shanghai Base Biotech, a base editing company, completed an A1 financing that brought in tens of millions of dollars, according to a release. BaseBio develops base editing tools and off-the-shelf Super-NK cell therapies. The financing will be used to advance the company's candidates in its base editing therapeutic pipeline, including eight general-purpose off-the-shelf Super-NK products and in vivo editing therapies. The A1 round was led by Hong Kong's Great Eagle VC, BV Baidu Ventures, Xinxi Capital, Guangda Huitong, UK SPARK VC and other investors. Previously, BaseBio raised $14 million in Angel funding. More details....

Share this with colleagues: